PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

20000298-4 IPOS COPY

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 47/02, 47/26, 31/47

A1

(11) International Publication Number: WO 99/62560

(43) International Publication Date: 9 December 1999 (09.12.99)

(21) International Application Number: PCT/US99/10189

(22) International Filing Date: 10 May 1999 (10.05.99)

(30) Priority Data:
60/088,280 5 June 1998 (05.06.98) US

(71) Applicant *(for all designated States except US)*: WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: DANIEL, Jane, Ellen [US/US]; 1 Claridge Drive, Verona, NJ 07044 (US). HARRIS, Michael, Ray [US/US]; 178 College View Drive, Hackettstwon, NJ 07840 (US). HOKANSON, Gerard, Clifford [US/US]; 1 Hunter Drive, Long Valley, NJ 07853 (US). WEISS, Jay [US/US]; 63 Independence Drive, East Brunswick, NJ 08810 (US).

(74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Moris Plains, NJ 07950 (US) et al.

(81) Designated States: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: STABILIZATION OF COMPOSITIONS CONTAINING ACE INHIBITORS USING MAGNESIUM OXIDE

(57) Abstract

The present invention is directed to ACE inhibitor–containing compositions stabilized by the presence of magnesium oxide. Preferably, the ACE inhibitor, quinapril, is protected from certain forms of degradation when prepared in a pharmaceutical composition consisting essentially of magnesium oxide as the stabilizing agent. The presence of magnesium oxide also lends itself to favorable processing conditions during the manufacture of ACE inhibitor–containing compositions, especially processing by wet granulation.